<?xml version="1.0" encoding="UTF-8"?>
<p id="para0004">The advent of direct acting antiviral (DAA) short-course, well-tolerated therapy has dramatically altered the hepatitis C virus (HCV) treatment landscape. Response rates over 95% are leading to dramatic reductions in liver-related mortality as well as new global targets to eliminate HCV as a public health threat by 2030 (
 <xref rid="bib0021" ref-type="bibr">N. Janjua et al., 2018</xref>; 
 <xref rid="bib0041" ref-type="bibr">World Health Organization, 2019</xref>). However, increasing injecting drug use and the epidemic of drug overdose-related deaths in North America threaten to arrest or even reverse the progress heralded by the DAA era among people who use drugs with HCV and the morbidity, mortality and well-being of all people who use drugs, regardless of HCV status.
</p>
